factor VIII inhibitor

factor VIII inhibitor

IgG alloantibodies to factor VIIIc that inhibits coagulation, which occur in up to 50% of Pts with severe hemophilia A; factor VIII antibodies may arise spontaneously in inflammatory diseases–eg, SLE, rheumatoid arthritis, and ulcerative colitis, or with ↑ age, during post-partum period, or in drug reactions Mechanism Factor VIII inhibitor inactivates factor VIII by steric prevention of interaction of factor VIII with vWF, phospholipids, activated factors IX and X, and thombin, and by proteolysis. See Bethesda units, Factor VIII.
References in periodicals archive ?
Qualitative variables like gender, factor VIII inhibitor level was reported as frequency and percentages.
Most of the time the disorder can be attributed to a factor VIII inhibitor (acquired haemophilia A-AHA) (5), but inhibition of other factors is also a possibility.
The Bethesda assay (factor VIII inhibitor screening) was negative for an inhibitor.
Dai et al., "Characterization of an acquired factor VIII inhibitor and plasmapheresis therapy in a patient with bullous pemphigoid," Thrombosis and Haemostasis, vol.
These agents (factor VIII inhibitor bypassing agent or recombinant factor VIIa), in spite of the fact that they do not contain factor VIII are effective in these patients because they bypass the factor VIII deficiency by increasing the activity of other coagulation factors.
He was discharged five days later in good condition, with a PTT of 49 s, factor VIII level of 0.09 IU/mL, factor VIII inhibitor level of 2.34 Bethesda Units/mL, and creatinine of 105 mmol/L.
Life-threatening sublingual hematoma in a severely hemophilic patient with factor VIII inhibitor. J Oral Maxillofac Surg.
Her factor VIII level was 2.3% and her factor VIII inhibitor level was 25 Bethesda units (measure of the level of inhibitor to coagulation factor VIII; equal to the amount of inhibitor in patient plasma that will inactivate 50% of factor VIII in an equal volume of normal plasma after a 2-h incubation period.
The advantages of giving as little factor VIII as possible would be avoiding the risk of developing factor VIII inhibitor antibodies or emergent infection and minimising the risk of acute thrombosis (including stent thrombosis) due to excessive factor VIII or coronary vasospasm after DDAVP.
Fulcher, "Localization of epitopes for human factor VIII inhibitor antibodies by immunoblotting and antibody neutralization," Blood, vol.
Factor VIII inhibitor formation in case 1 occurred 6 months after giving birth; underlying disorders were not identified in cases 2 or 3.